At a glance
ClinicalIndex Comparison RecordN/ACompleted· 44 enrolled
Drug / intervention
melphalan +7 moredrug
Likely dose
melphalan 140 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Partially HLA-Mismatched Related Donor Hematopoietic Stem Cell Transplantation Using Killer Immunoglobulin Receptor and Human Leukocyte Antigen Based Donor Selection
In Brief
A clinical study evaluating melphalan, fludarabine, and 6 other interventions for Hematologic Malignancy. Completed, enrolled 44 participants across 1 site.
Detailed Summary
This study will test whether half matched donors with favorable KIR genes will reduce the risk of cancer recurring after transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematologic Malignancy
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartAug 2016
First PostedAug 2016
Primary CompletionNov 2023
TodayJul 2026
First PostedAug 26, 2016
Enrollment StartAug 23, 2016
Primary CompletionNov 20, 2023
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 9.8 years ago
Interventions
melphalandrug
melphalan (140 mg/m2 IV on day -7)
fludarabinedrug
fludarabine (40 mg/m2/d on days -5 through -2)
thiotepadrug
thiotepa (5 mg/kg IV on day -67)
Cyclophosphamidedrug
cyclophosphamide (50 mg/kg IV on day +3 and +4)
Mesnadrug
Mycophenolate Mofetildrug
(15 mg/kg PO/IV TID)
Filgrastimdrug
Tacrolimusdrug